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ABSTRACT 
 
Background: Systemic administration of linear polyethylenimine-DNA complexes (L-PEI/DNA) 
results in transient expression of the transgene in the lung. In this study we analyzed the side 
effects associated with L-PEI-mediated transfection.  
Methods: Mice of weight ranging from 16 to 25 g received increasing amounts of L-PEI/DNA 
intravenously. Gene expression was evaluated using luciferase as a reporter gene. Toxicity was 
evaluated by monitoring the appearance of a shock after injection, the survival of the animals and 
the microscopic damages in the tissues. Adherence of blood cells on the endothelium was 
measured after immuno-staining of the CD11b positive cells. Anti-aggregant treatments were 
used in order to prevent the formation of thrombi. 
Results: Increasing the quantity of L-PEI/DNA resulted in an important augmentation of the 
luciferase activity in the lung, but was associated with liver necrosis and death. Lethality was 
reached at lower doses in old mice than in the younger, suggesting also an influence of age. 
Transfection was associated with an augmentation of adhesion of CD11b positive cells on the 
endothelium, without evidence of lung injury. Anti-aggregant treatments (aspirin, EDTA, heparin 
or clopidogrel) decreased the L-PEI-mediated transfection, supporting the hypothesis that 
formation of thrombi was necessary for the blockade of DNA-complexes in the lung capillaries 
and subsequent transfection of lung cells. 
Conclusion: This study demonstrates that L-PEI/DNA activates the lung endothelium and forms 
aggregates, a side effect linked to the transfection efficiency. In addition, the therapeutic dose-
window is too narrow for any clinical application.  
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INTRODUCTION 
 
Because of their small size and physical stability, L-PEI/DNA complexes display high 
transfection efficiency in vitro and in vivo (1-9). The particularly high capacity of L-PEI to 
deliver genes into the lungs of mice after an intravenous injection contributed to make of L-PEI a 
very promising vector for pulmonary diseases. However, some important limitations hindered the 
therapeutic development of this technique.  
A first limitation comes from the observation that L-PEI-mediated gene expression is strongly 
restricted to the type II pneumonocytes, an epithelial cell type present in the alveoli. One 
prevailing hypothesis to explain the selective transfection of the lung is that L-PEI/DNA 
complexes are forming aggregates with blood components (7) and that these aggregates are 
blocked mechanically in the small capillaries of the lung. Despite the fact that it does not explain 
the selectivity toward type II pneumonocytes, this mode of functioning would not predispose the 
transfer of this technology to the clinic. A second limitation is due to the very short duration of 
expression of the transgene in the lung (8). Since expression is not sustained for more than one 
day, most of the applications and especially the correction of genetic abnormalities can not be 
approached by this method.  
In order to determine whether or not these obstacles could be overcome, we focused our attention 
on the side effects associated with L-PEI/DNA intravenous injections. We present evidence that 
lung cell transfection is observed only when a close to lethal dose of L-PEI/DNA is injected. In 
the minutes following the injections the animal are shocked and some of them will eventually die. 
Transfection is associated with liver damages and lung endothelium activation. Furthermore, lung 
transfection is strongly decreased when animals are pretreated with anti-aggregant molecules 
supporting the hypothesis that lung transfection is linked to the formation of micro-thrombi.  
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MATERIALS AND METHODS 
 
 Plasmid constructs and L-PEI/DNA complexes formation 
 
 Plasmid pCMV-Luc (8) was extracted with Qiagen Endo-free-Mega-prep columns (Qiagen, 
Chatsworth, CA). 
 Linear polymers of ethylenimine (L-PEI) with a mean molecular weight of 22kDa (Exgen 
500; Euromedex, Souffleweyersheim, France) were used as transfection reagent. L-PEI/DNA 
complexes with a ratio of L-PEI nitrogen to DNA phosphate of 10 were prepared. These 
complexes were performed in a solution of 5% w/v glucose (final) in order to produce small 
particles (3). This was performed in a two step procedure as described hereafter for the 
preparation of a standard quantity of 50 µg L-PEI/DNA complexes. In a first tube 15 µl 0.1 M L-
PEI were diluted at RT with 60 µl water and 25 µl Glucose 25%. In a second tube, 50 µl DNA (1 
µg/µl) were diluted with 25 µl of water and 25 µl glucose 25%. The 100 µl of L-PEI were then 
added quickly to the 100 µl DNA and mixed thoroughly. After an incubation of 15 min at RT, the 
200 µl containing 50 µg L-PEI/DNA were injected. When various amounts of L-PEI/DNA were 
injected (from 20 to 150 µg DNA), the final volume of the injected solution was kept constant to 
200 µl. In these cases, the quantity of L-PEI was adjusted to the amount of DNA in order to 
maintain a ratio of 10 (L-PEI nitrogen to DNA phosphate). 
 
Luciferase measurements. 
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The luciferase assay was performed using the Luciferase Assay System (Promega) as 
recommended by the manufacturer. Briefly, tissues were extracted and cut in small pieces using a 
razor blade. One hundred µl of Cell Culture Lysis reagent for each 20 mg of tissue were used to 
resuspend the extracts, which were then immediately frozen at –20°C. The following day, the 
samples were defrost and brought to RT. After a brief centrifugation, 10 µl of extracts were 
mixed with 100 µl of Luciferase Assay substrate and the luciferase activity was measured during 
10 s on a photoluminometer (Promega). The concentration of protein was measured using the 
DC-comp Bio-Rad assay, and the luciferase activities were calculated as the number of 
RLU/10s/mg of protein (RLU = Reference Light Unit). Using purified firefly luciferase in the 
same experimental conditions, we determined that 2 ng of this enzyme produced 10
8
 RLU/10s. 
 
Animal care and procedures 
 
Female SWISS nude (IFFA-CREDO, Marcy l’Etoile, France) with weight ranging from 16 (4 
weeks) to 25 g (≥10 weeks) were injected rapidly (approximately 5s) in the tail vein using 1 ml 
syringes with 29G x 1/2 needles (for insulin injection, Becton Dickinson, Meylan, France). At 
various times following the injection, the mice were killed by cervical dislocation. Heart, lung, 
spleen, liver, and kidneys were collected, washed with PBS and used for luciferase activity 
measurements. 
For anti-aggregant treatments, 200 µg/kg aspirin (Synthelabo, France), or 5 000 IU/kg heparin or 
1µg EDTA (Sigma) in 200 µl PBS were injected intravenously into 16 g mice. One hour later 
they were injected with 50 µg L-PEI/DNA complexes. One day later the different organs were 
analyzed for their luciferase content. Note that other concentrations of aspirin were tried (100 and 
400 µg/kg) and produced similar results without any toxicity. 
  
 6 
In parallel, 16 g mice received 50 mg/day/kg of clopidogrel (Plavix, Sanofi-Pharmacia, France) 
orally for 3 days, followed by one iv injection of 50 µg L-PEI/DNA. One day later, luciferase 
expression was measured in the lung.  
 
CD11-b Immunolabeling 
 
 Sixteen gram mice received an intravenous injection of L-PEI (15 µl 0.1 M in 200 µl 5% 
glucose), DNA (50 µg in 200µl 5% glucose), L-PEI-DNA (15 µl 0.1 M L-PEI + 50 µg DNA in 
200 µl 5% Glucose) or glucose only. Three hours later, the mice were killed by cervical 
dislocation. Frozen sections of the lung were allowed to dry overnight at RT and fixed during 10 
min with acetone at –20°C. Non-specific binding was avoided by incubating fixed tissues in 3% 
bovine serum albumin (BSA) in PBS (30 min at RT). Rat anti mouse CD11-b antibodies (Serotec, 
Oxford, England) were diluted at 1/50 and incubated overnight at 4°C. Secondary, peroxidase-
conjugated anti rat immunoglobulins (DAKO, Copenhagen, Denmark) was diluted to 1/50 and 
incubated for 1h at RT. Diaminobenzidine tetrahydrochloride (Sigma, Saint Quentin Fallavier, 
France) was used as chromogenic substrate. A counterstaining of the nuclei was then performed 
using hematoxylin. Normal rat IgG at the same concentration as the primary antibodies served as a 
negative control. Sections were examined and counted on a Zeiss Axioskop microscope (40x 
magnification), using a triCCD camera (Sony) and a SAMBA 2005 software (SAMBA 
technologies, Grenoble). 
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RESULTS  
 
L-PEI-mediated transfection of the lung is toxic. 
 
We have already shown that injection of 50 µg of L-PEI/DNA complexes intravenously in 16 g 
mice (4-5 weeks old) results in a strong expression of the reporter gene in the lung (8). This is 
associated with toxicity, since most of the animals are shocked within the first 20 minutes 
following the i.v. injection.  
In an attempt to determine the therapeutic dose-window of L-PEI/DNA (i.e. an efficient 
transfection of the lung but without shock), we injected increasing amounts of DNA complexes 
into 16 g mice (Figure 1). In these experiments, the L-PEI and DNA concentrations were 
increased proportionally in order to keep the same L-PEI/DNA ratio. As well, the injected 
volume and rate of injection were kept constant (200 µl injected rapidly with a syringe). 
Luciferase expression in the lung started to be significant when at least 40 µg L-PEI/DNA were 
injected (Figure 1). At lower doses, gene transfer was inefficient. Injection of 50 µg L-PEI/DNA 
resulted in an increased expression of the transgene. At this dose, most of the animals were 
transiently shocked and 2 out of 42 of them died. Increasing the quantity of complexes to 100 µg 
L-PEI/DNA had no dramatic influence on the lethality but was associated with the appearance of 
necrotic areas in the liver (Figure 2) and higher levels of gene transfer in the lung. When a dose 
of 150 µg L-PEI/DNA was reached, all the treated animals died of the shock in the first 30 
minutes (3/3). In older 25 g mice, lethality was observed as soon as 85 µg L-PEI/DNA complexes 
were injected (25%). This effect was even more pronounced at higher doses. All 25 g animals 
died of an injection of 100 µg LPEI-DNA, suggesting that older animals were more sensitive to 
L-PEI/DNA (Table 1). 
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We evaluated the efficacy of lung transfection in animals of growing sizes (between 4 and 30 
weeks, from 16 to 25 g in weight) one day after an intravenous injection of 50 µg L-PEI/DNA. 
As shown in Figure 3, luciferase expression was 600 times more elevated in the lung of young 
animals then in the older ones (2.8 ± 0.4 10
7
 versus 4.7 ± 1.9 10
4
 RLU/mg prot/10s). Thus, the 
usual dose of 50 µg L-PEI/DNA can produce significantly different results if the weight of the 
mice differs. 
Histologically, no major tissue damage was noticed in the lung, spleen, kidneys, stomach, guts, 
skin and muscles (data not shown), but necrotic areas were always observed in the liver of 
animals which received high doses of L-PEI/DNA (Figure 2 A and B). In contrast, the lung did 
not present overt injury or infiltration (Figure 2 C), but an increased number of blood cells 
overlaying the endothelial surface was observed as soon as 30 min after L-PEI/DNA injection. 
This accumulation of lung cells was maximum at 3h (Figure 2C) but still visible at 24h (data not 
shown).  
 
L-PEI increases the adhesiveness of white blood cells 
 
We then quantified this phenomenon by counting the number of CD11-b positive cells in the lung 
of sixteen-gram mice treated with L-PEI, DNA, L-PEI/DNA or glucose only. Frozen sections of 
the lung were immuno-stained with an anti-CD11-b 3h after injection. The results indicated that 
L-PEI alone or complexed with DNA can induce a 3 fold increased of the number of CD11-b 
positive cells including monocytes, granulocytes, natural killer (NK), some activated B 
lymphocytes and CD8 positive CTL on the surface of the lung endothelium (Figure 4). 
 
L-PEI/DNA-mediated gene transfer is influenced by anti- or pro-aggregant treatments. 
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We suspected at first that the toxicity as well as the lung tropism of L-PEI/DNA complexes could 
be related to a mechanical block of the DNA complexes in the lung capillaries. To test this 
hypothesis, we pretreated 16 g mice with 4 anti-coagulants before iv injection of 50 µg L-
PEI/DNA.  
Mice received aspirin, EDTA or heparin intravenously one hour before the L-PEI/DNA 
complexes. Each of these pre-treatments induced a significant decrease in the level of luciferase 
expression in the lung (Figure 5). Other animals received clopidogrel orally for 3 days, followed 
by one iv injection of 50 µg L-PEI/DNA (Figure 6). Clopidogrel had a lower activity than aspirin 
but still induced a significant decreased of expression in the treated (9.3 ± 0.3 x 10
6
 RLU/mg 
prot/10s) versus the control animals (24.1 ± 0.2 x 10
6
 RLU/mg prot/10s; n=5). 
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DISCUSSION 
 
Several studies have demonstrated that it is possible to transfer and express a foreign gene by 
injecting intravenously lipo- or polyplex (1, 10-15). L-PEI is one of the most efficient polycations 
when injected intravenously: as soon as two hours after L-PEI/DNA iv injection, lung cells and 
especially pneumonocytes are expressing the transgene (8, 9). Up to 5% of the lung cells are 
possibly transfected and can produce nano-grams of luciferase. Several other cationic vectors 
gave similar results in terms of rapidity of expression (16), transfected organ (11, 12, 16-19), 
duration of gene expression and pattern of cytokine response (20-23). This suggests that cationic-
based vectors have similar mode of functioning.  
Several limitations still hinder the widespread application of systemic administration of non-viral 
vectors. Among them we can mention (i) the high selectivity of most, if not all, of the cationic 
vectors for the lung, (ii) the very transient aspect of transgene expression, too brief to be used for 
the correction of genetic abnormalities. In this study we present evidences that toxicity of 
cationic particles is also an important issue. 
 Cationic molecules must be toxic in order to be efficient and both properties can not be 
dissociated. Indeed, we show that L-PEI-mediated transfection of the lung requires the use of a 
close to lethal quantity of L-PEI/DNA complexes and that transfection is necessarily associated 
with the formation of thrombi. The toxicity of L-PEI-mediated transfection is obvious as soon as 
15 min after injection of 50 µg L-PEI/DNA. A shock is observed in the following minutes but is 
overcome in 95 % of the cases. Increasing the dose up to 100 µg is associated with a powerful 
enhancement of the transfection, but most of the animals will suffer liver damages. In addition, 
the toxicity is observed at lower doses in older animals. Thus, the therapeutic dose-window is 
probably too narrow for any clinical application. 
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So far, the prevailing hypothesis to explain the lung tropism of L-PEI/DNA complexes is that 
they are forming large aggregates with proteins such as IgM, fibrinogen, fibronectin and 
complement C3 and by interacting with erythrocytes (7, 24). These aggregates could be blocked 
in the lung capillaries (25), thus contributing to the overall toxicity. Pulmonary microvascular 
endothelial cells are known to play an active role in the events that lead to vascular damage in the 
inflammatory response. The endothelial surface, normally antithrombogenic, can respond to 
certain stimuli, generally injurious, by becoming strongly procoagulant. Such transformations of 
endothelial functions may be important for the entrapment and disposal of phagocytosed particles 
and may result in it’s transient opening suggested by Zou et al. (9). This would be associated with 
an increased accessibility to epithelial cells. Once activated, the endothelium can bind blood cells 
more efficiently. Platelets may enhance the monocyte-endothelium interaction (26, 27). Our 
findings that L-PEI/DNA-mediated transfection can be inhibited by anti-aggregant treatments 
(aspirin, EDTA, heparin, clopidogrel) and that the number of CD11-b positive cells on the surface 
of the endothelium is increasing after L-PEI treatment strongly support the hypothesis of the 
transient activation and opening of the endothelium barrier. 
Polycationic molecules like PEI can be covalently coupled to hydrophilic polymers like 
poly(ethylene glycol) (PEG) (4, 7) to transferrin (24) or to antibodies (4, 28). By reducing the 
surface charge of the shielded particles the formation of aggregates is strongly decreased. This 
can result in a decreased expression of the reporter gene in the lung and an increased transfection 
of subcutaneous tumors (24). Antithrombogenic treatments are also associated with a decreased 
transfection of the lung, but without concomitant increased of the transfection of other organs 
including subcutaneous tumors (data not shown). Thus preventing the formation of thrombi does 
not produce the same effect than reducing the surface charge of the complexes. One hypothesis is 
that the shielding, but not antithrombic treatments, prolongs the circulation of the complexes in 
  
 12 
the blood, allowing their passive accumulation in organs with a disorganized vascularization like 
tumors. It seems reasonable to assume that these shielded particles will have a decreased toxicity 
and will thus be promising vectors. Nonetheless their biophysical properties, toxicity and 
efficiency will depend on the quality of the shielding compound(s) (4) and of the chemical 
methods used for the generation of these particles. 
In conclusion, our study establishes that toxicity is a major concern when using polycationic 
particles to transfer DNA by systemic application, and that this toxicity is inherent to their mode 
of functioning. This will be helpful for the definition and generation of new molecules with 
increased performances and decreased toxicity. 
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LEGENDS 
 
Figure 1: Transfection efficiency is dose dependent. Nude mice of 16 g received the indicated 
amounts of L-PEI/DNA iv one day before sacrifice and measurement of the luciferase activity in 
their lungs. Representative experiment (n=3 per group) repeated 2 times. 
 
Figure 2: L-PEI-mediated liver toxicity. A/ Liver section of a glucose treated animal. B/ Liver 
section of a 16 g mouse 24h after injection of 100 µg L-PEI/DNA intravenously (magnification: 
x20 for A and B). C/ Adhesion of blood cells (indicated by arrowheads) on the lung endothelium 
(magnification: x40). 
 
Figure 3: Transfection efficiency decreases with the weight of the mice. Mice of increasing 
weight (n=3 per group) received 50 µg of L-PEI/DNA iv one day before sacrifice and 
measurement of the luciferase activity in their lungs. As a whole, this experiment was performed 
only once with the 6 groups at the same time. These results were then repeated in independent 
experiments on a total of 42 sixteen grams mice and 21 mice of 25 grams.  
 
Figure 4: CD11-b positive blood cells accumulate on the endothelium surface. Three hours 
after L-PEI/DNA injection (50 µg into a 16 g animal), the lungs were dissected and stained with 
an antiCD11-b antibody and counterstained with hematoxylin. The percentage of CD11b positive 
cells (brown) among the total lung cells (blue) was counted automatically using a Samba 
software after digitalization of the pictures. Eight animals per group were included in this study 
and 5 independent fields at a 40x magnification were counted for each animal.  
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Figure 5: Aspirin, EDTA and heparin inhibit lung transfection. Sixteen gram mice (n=3 per 
group) were pre-treated with 200 mg/kg aspirin, 1µg EDTA or 5 IU/g heparin intravenously one 
hour before receiving 50 µg L-PEI/DNA. One day later they were sacrificed and the luciferase 
activities present in the lungs were measured. This experiment was repeated three times with 
aspirin. 
 
Figure 6: Clopidogrel inhibits lung transfection: Sixteen g mice (n=5 per group) received 50 
mg/Kg/day clopidogrel or water only (control group) orally for 3 days before they were injected 
iv with 50 µg L-PEI/DNA. One day later they were sacrificed and the luciferase activities present 
in the lungs were measured. In each organ the p value was always <0.05 using the Mann-Withney 
test (when the clopidogrel and control groups were compared). 
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Weight  50µg 85 µg 100 µg 150 µg 
     
16 g 2/42 (4,76%) ND 0/6 (0%) 3/3 (100%) 
25 g 0/21(0%) 3/12 (25%) 3/3 (100%) ND 
     
Table 1: Percentage of dead mice 24 hours after injection of the indicated amount of DNA. DNA 
was mixed with 10 eq L-PEI in 200 µl 5% glucose and injected rapidly in the tail vein.  
 
